How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,654 results for

Polypharmacy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Prevalence of Central Nervous System Polypharmacy and Associations with Overdose and Suicide-Related Behaviors in Iraq and Afghanistan War Veterans in VA Care 2010–2011 (PubMed)

Prevalence of Central Nervous System Polypharmacy and Associations with Overdose and Suicide-Related Behaviors in Iraq and Afghanistan War Veterans in VA Care 2010–2011 The increase in the quantities of central nervous system (CNS)-acting medications prescribed has coincided with increases in overdose mortality, suicide-related behaviors, and unintentional deaths in military personnel deployed in support of the wars in Iraq and Afghanistan. Data on the extent and impact of prescribing (...) multiple CNS drugs among Iraq and Afghanistan Veterans (IAVs) are sparse.We sought to identify the characteristics of IAVs with CNS polypharmacy and examine the association of CNS polypharmacy with drug overdose and suicide-related behaviors controlling for known risk factors.This cross-sectional cohort study examined national data of Iraq and Afghanistan Veterans (N = 311,400) who used the Veterans Health Administration (VHA) during the fiscal year 2011. CNS polypharmacy was defined as five or more

Full Text available with Trip Pro

2016 Drugs - real world outcomes

182. Implications of a clinical medication review and a pharmaceutical care plan of polypharmacy patients with a cardiovascular disorder. (PubMed)

Implications of a clinical medication review and a pharmaceutical care plan of polypharmacy patients with a cardiovascular disorder. Background A clinical medication review, including patient involvement, is expected to improve pharmaceutical care. Objective To determine whether a clinical medication review followed by a pharmaceutical care plan decreases the number of potential drug-related problems (DRPs) and pharmaceutical care issues (PCIs) and leads to a positive effect on relevant (...) clinical and laboratory parameters for elderly cardiovascular patients with multiple drug use. Setting Randomized controlled trial in eight primary care settings in the Netherlands. Method Elderly polypharmacy patients with a cardiovascular disorder were randomized into two groups. Intervention patients received a clinical medication review, followed by a pharmaceutical care plan developed in cooperation between these patients' pharmacists and general practitioners (GPs), and agreed to by the patients

Full Text available with Trip Pro

2017 International journal of clinical pharmacy Controlled trial quality: uncertain

183. Assessing medication burden and polypharmacy: finding the perfect measure (PubMed)

Assessing medication burden and polypharmacy: finding the perfect measure 28271722 2018 05 28 2018 11 13 1751-2441 10 4 2017 04 Expert review of clinical pharmacology Expert Rev Clin Pharmacol Assessing medication burden and polypharmacy: finding the perfect measure. 345-347 10.1080/17512433.2017.1301206 Gnjidic Danijela D a Faculty of Pharmacy and Charles Perkins Centre , University of Sydney , Sydney , NSW , Australia. Tinetti Mary M b Department of Internal Medicine , Yale School of Medicine (...) Prescribing statistics & numerical data Polypharmacy Practice Patterns, Physicians' standards Polypharmacy deprescribing older adults 2017 3 9 6 0 2018 5 29 6 0 2017 3 9 6 0 ppublish 28271722 10.1080/17512433.2017.1301206 PMC5477055 NIHMS863644 Clin Pharmacol Ther. 2012 Mar;91(3):521-8 22297385 J Clin Epidemiol. 2012 Sep;65(9):989-95 22742913 J Gerontol A Biol Sci Med Sci. 2017 Feb;72 (2):259-265 27384327 BMJ. 2016 Jun 15;353:i2868 27306620 Cochrane Database Syst Rev. 2014 Oct 07;(10):CD008165 25288041 J

Full Text available with Trip Pro

2017 Expert review of clinical pharmacology

184. Cytochrome P450‐mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy (PubMed)

Cytochrome P450‐mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy Although clinically widespread, scientific evidence for antipsychotic polypharmacy is still limited. Combining different drugs increases the potential for drug-drug interactions, enhancing the risk of adverse drug reactions. We aimed to unravel the potential pharmacokinetic interactions between risperidone (RIS) and perazine.Using a therapeutic drug monitoring database containing

Full Text available with Trip Pro

2017 British journal of clinical pharmacology

185. Polypharmacy among Underserved Older African American Adults (PubMed)

Polypharmacy among Underserved Older African American Adults The purpose of the present study was to examine correlates of polypharmacy among underserved community-dwelling older African American adults. Methods. This study recruited 400 underserved older African Americans adults living in South Los Angeles. The structured face-to-face interviews collected data on participants' characteristics and elicited data pertaining to the type, frequency, dosage, and indications of all medications used (...) by participants. Results. Seventy-five and thirty percent of participants take at least five and ten medications per day, respectively. Thirty-eight percent of participants received prescription medications from at least three providers. Inappropriate drug use occurred among seventy percent of the participants. Multivariate analysis showed that number of providers was the strongest correlate of polypharmacy. Moreover, data show that gender, comorbidity, and potentially inappropriate medication use are other

Full Text available with Trip Pro

2017 Journal of aging research

186. Successful withdrawal from high-dose benzodiazepine in a young patient through electronic monitoring of polypharmacy: a case report in an ambulatory setting (PubMed)

Successful withdrawal from high-dose benzodiazepine in a young patient through electronic monitoring of polypharmacy: a case report in an ambulatory setting Dependence on high-dose benzodiazepines (BZDs) is well known and discontinuation attempts are generally unsuccessful. A well established protocol for high-dose BZD withdrawal management is lacking. We present the case of withdrawal from high-dose lorazepam (>20 mg daily) in an unemployed 35-year-old male outpatient through agonist

Full Text available with Trip Pro

2017 Therapeutic Advances in Psychopharmacology

187. Identifying, highlighting and reducing polypharmacy in a UK hospice inpatient unit using improvement Science methods (PubMed)

Identifying, highlighting and reducing polypharmacy in a UK hospice inpatient unit using improvement Science methods Polypharmacy, the concurrent use of multiple medications by one individual is a growing global issue driven by an ageing population and increasing prevalence of multi-morbidity[1]. Polypharmacy can be problematic: interactions between medications, reduced adherence to medication, burden of medication to patients, administration time, increased risk of errors and increased cost (...) . Quality improvement methods were applied to identify and highlight polypharmacy patients with the aim of reducing their average number of regular tablets/capsules per day by 25%. The project was delivered within a UK based 27 bedded hospice inpatient unit. A series of PDSA cycles studied interventions focusing on the identification of patients with polypharmacy, the highlighting of these patients to prescribers for review and the views of patients about their medication. For the purposes of the study

Full Text available with Trip Pro

2017 BMJ Quality Improvement Reports

188. Trends in Central Nervous System–Active Polypharmacy Among Older Adults Seen in Outpatient Care in the United States (PubMed)

Trends in Central Nervous System–Active Polypharmacy Among Older Adults Seen in Outpatient Care in the United States 28192559 2018 10 22 2018 11 13 2168-6114 177 4 2017 04 01 JAMA internal medicine JAMA Intern Med Trends in Central Nervous System-Active Polypharmacy Among Older Adults Seen in Outpatient Care in the United States. 583-585 10.1001/jamainternmed.2016.9225 Maust Donovan T DT Department of Psychiatry, University of Michigan, Ann Arbor2Center for Clinical Management Research, VA (...) States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States JAMA Intern Med 101589534 2168-6106 AIM IM Aged Aged, 80 and over Ambulatory Care Female Humans Male Mental Disorders drug therapy Pain drug therapy Polypharmacy United States 2017 2 14 6 0 2018 10 23 6 0 2017 2 14 6 0 ppublish 28192559 2601416 10.1001/jamainternmed.2016.9225 PMC5378654 NIHMS836615 J Clin Psychiatry. 2015 Jan;76(1):40-4 25188822 J Am Geriatr Soc. 2015 Nov;63(11):2227-46 26446832

Full Text available with Trip Pro

2017 JAMA Internal Medicine

189. Polypharmacy in Zoological Medicine (PubMed)

Polypharmacy in Zoological Medicine Polypharmacy is a term that describes the inappropriate, concurrent use of multiple drugs in an individual patient. Zoological medicine practitioners must take approved agents (veterinary or human) and extrapolate their use to non-approved species often with little species-specific pharmacological evidence to support their decisions. When considering polypharmacy, even less information exists concerning multi-drug pharmacokinetics, pharmacodynamics (...) , or potential drug-drug interactions in non-domestic species. Unfortunately, captive, zoological species are susceptible, just like their domestic counterparts, to chronic diseases and co-morbidities that may lead to the usage of multiple drugs. Polypharmacy is a recognized and important issue in human medicine, as well as an emerging issue for veterinarians; thus, this paper will discuss the novel, potential risks of polypharmacy in zoological medicine. Hopefully, this discussion will help bring

Full Text available with Trip Pro

2017 Pharmaceutics

190. Clinician agreement and influence of medication‐related characteristics on assessment of polypharmacy (PubMed)

Clinician agreement and influence of medication‐related characteristics on assessment of polypharmacy It is not known how clinicians assess polypharmacy or the medication-related characteristics that influence their assessment. The aim of this study was to examine the level of agreement between clinicians when assessing polypharmacy and to identify medication-related characteristics that influence their assessment. Twenty cases of patients with varying levels of comorbidity and polypharmacy (...) were used to examine clinician assessment of polypharmacy. Medicine-related factors within the cases included Beers and STOPP Criteria medicines, falls-risk medicines, drug burden index (DBI) medicines, medicines causing postural hypotension, and pharmacokinetic drug-drug interactions. Clinicians were asked to rate cases on the degree of polypharmacy, likelihood of harm, and potential for the medication list to be simplified. Inter-rater reliability analysis, correlations, and multivariate logistic

Full Text available with Trip Pro

2017 Pharmacology research & perspectives

191. Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing (PubMed)

Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing The majority of patients respond to antipsychotic monotherapy at standard doses, but a subset of patients will require more heroic measures that include antipsychotic polypharmacy and high-dose monotherapy. Indeed, research has shown that roughly 30% of patients with psychosis are prescribed multiple antipsychotic medications. We discuss the potential benefits and challenges

Full Text available with Trip Pro

2017 BJPsych bulletin

192. Prevalence and Geographic Variations of Polypharmacy Among West Virginia Medicaid Beneficiaries (PubMed)

Prevalence and Geographic Variations of Polypharmacy Among West Virginia Medicaid Beneficiaries West Virginia (WV) residents are at high risk for polypharmacy given its considerable chronic disease burdens.To evaluate the prevalence, correlates, outcomes, and geographic variations of polypharmacy among WV Medicaid beneficiaries.In this cross-sectional study, we analyzed 2009-2010 WV Medicaid fee-for-service (FFS) claims data for adults aged 18-64 (N=37,570). We defined polypharmacy (...) as simultaneous use of drugs from five or more different drug classes on a daily basis for at least 60 consecutive days in one year. Multilevel logistic regression was used to explore the individual- and county-level factors associated with polypharmacy. Its relationship with healthcare utilization was assessed using negative binomial regression and logistic regression. The univariate local indicators of spatial association method was applied to explore spatial patterns of polypharmacy in WV.The prevalence

Full Text available with Trip Pro

2017 The Annals of pharmacotherapy

193. Polypharmacy: a challenge for the primary health care of the Brazilian Unified Health System (PubMed)

Polypharmacy: a challenge for the primary health care of the Brazilian Unified Health System To characterize the polypharmacy in primary health care patients and to identify its associated factors.This is a cross-sectional, exploratory, and evaluative study, part of the Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos - Serviços, 2015 (PNAUM - National Survey on Access, Use and Promotion of Rational Use of Medicines - Services, 2015). The variable (...) of interest was polypharmacy, defined as the use of five or more medicines. We sought to identify the association of sociodemographic variables and indicators of health conditions to polypharmacy. For group comparison, the Pearson's Chi-square test was used. The association between polypharmacy and explanatory variables was evaluated by logistic regression model (p < 0.05). The quality of the adjustment was verified by Hosmer-Lemeshow test.The prevalence of polypharmacy among medicine users was 9.4% (95

Full Text available with Trip Pro

2017 Revista de saúde pública

194. Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus (PubMed)

Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus 28674868 2018 11 30 1619-1560 27 Suppl 1 2017 07 Clinical autonomic research : official journal of the Clinical Autonomic Research Society Clin. Auton. Res. Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus. 33-34 10.1007/s10286-017-0435-5 Vernino Steven S Department of Neurology

Full Text available with Trip Pro

2017 Clinical Autonomic Research

195. Poly-de-prescribing to treat polypharmacy: efficacy and safety (PubMed)

Poly-de-prescribing to treat polypharmacy: efficacy and safety The aim of this study was to evaluate efficacy and safety of poly-de-prescribing (PDP) based on the Garfinkel method in older people with polypharmacy.A longitudinal, prospective, nonrandomized study in Israel was carried out between 2009 and 2016. Comprehensive geriatric assessments were performed at home in people age ⩾66 years consuming ⩾6 prescription drugs. Exclusion criteria were life expectancy <6 months and a seeming (...) reduced (p < 0.002 in all). The rate of hospitalizations and mortality was comparable. Health improvement occurred within 3 months after de-prescribing in 83%, and persisted for ⩾2 years in 68%.This self-selected sample longitudinal research strongly suggests that the negative, usually invisible effects of polypharmacy are reversible. PDP is well tolerated and associated with improved clinical outcomes, in comparison with outcomes of older people who adhere to all clinical guidelines and take all

Full Text available with Trip Pro

2017 Therapeutic advances in drug safety

196. Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome (PubMed)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome Atypical antipsychotics (AAP) are the prevailing form of schizophrenia treatment today due to their low side effects and superior efficacy. Nevertheless, some issues still need to be addressed. First, there are still a large number of patients with treatment-resistant schizophrenia (TRS), which has led to a growing trend to resort to AAP polypharmacy with few side (...) effects. Most clinical treatment guidelines recommend clozapine monotherapy in TRS, but around one third of schizophrenic patients fail to respond to clozapine. For these patients, with clozapine-resistant schizophrenia AAP polypharmacy is a common strategy with a continually growing evidence base. Second, AAP generally have great risks for developing metabolic syndrome, such as weight gain, abnormality in glucose, and lipid metabolism. These metabolic side effects have become huge stumbling blocks

Full Text available with Trip Pro

2017 International journal of molecular sciences

197. Antipsychotic polypharmacy prescribing and risk of hospital readmission (PubMed)

Antipsychotic polypharmacy prescribing and risk of hospital readmission The aim of this study was to determine if there was an association between being discharged on antipsychotic polypharmacy (APP) and risk of readmission into secondary mental health care.Using data from the South London and Maudsley (SLAM) case register, service users with serious mental illness (SMI), discharged between 1st January 2007 and 31th December 2014, were followed up for 6 months. Patients were classified (...) as receiving either monotherapy or polypharmacy at index discharge. Multivariable Cox regression models were constructed, adjusting for sociodemographic, socioeconomic, clinical and service use factors.We identified 5523 adults who had been admitted at least once to SLAM, of whom 1355 (24.5%) were readmitted into secondary mental health care. In total, 15% (n = 826) of patients were discharged on APP and 85% (n = 4697) on monotherapy. Of these, 30.9% (n = 255) and 23.4% (n = 1100) were readmitted

Full Text available with Trip Pro

2017 Psychopharmacology

198. A dataset quantifying polypharmacy in the United States (PubMed)

A dataset quantifying polypharmacy in the United States Polypharmacy is increasingly common in the United States, and contributes to the substantial burden of drug-related morbidity. Yet real-world polypharmacy patterns remain poorly characterized. We have counted the incidence of multi-drug combinations observed in four billion patient-months of outpatient prescription drug claims from 2007-2014 in the Truven Health MarketScan® Databases. Prescriptions are grouped into discrete windows (...) of polypharmacy in a large US cohort, which can prioritize common drug combinations for future safety and efficacy studies.

Full Text available with Trip Pro

2017 Scientific data

199. Bad Medicine: Polypharmacy (PubMed)

Bad Medicine: Polypharmacy 29192108 2019 02 28 2019 02 28 1478-5242 67 665 2017 12 The British journal of general practice : the journal of the Royal College of General Practitioners Br J Gen Pract Bad Medicine: Polypharmacy. 562 10.3399/bjgp17X693737 Spence Des D Maryhill Health Centre, Glasgow. eng Journal Article England Br J Gen Pract 9005323 0960-1643 0 Prescription Drugs IM Br J Gen Pract. 2018 Feb;68(667):70 29371301 Drug Industry economics Health Care Costs Humans Polypharmacy Practice

Full Text available with Trip Pro

2017 The British Journal of General Practice

200. Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-Sectional Analysis (PubMed)

Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-Sectional Analysis A lack of gold standard treatment for autism spectrum disorders (ASD), no clear ASD management guidelines, and lack of evidence-based pharmacological interventions other than aripiprazole and risperidone elevate the risk of off-label prescribing and adverse effects among individuals with ASD, more so among adults.The aim of this study was to identify and compare the types (...) of prescription drug use, rates of polypharmacy, and characteristics associated with polypharmacy among adults with and without ASD in a retrospective cross-sectional analysis of a three-state Medicaid Analytic eXtract database (2000-2008).Adults aged 22-64 years with ASD (ICD9-CM code: 299.xx) were propensity score-matched to 'no ASD' controls by age, sex, and race. General polypharmacy (≥6 unique classes of prescription drugs in a year) and psychotropic polypharmacy (≥3 unique prescription drug classes

Full Text available with Trip Pro

2016 Drugs - real world outcomes

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>